{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T18:46:31Z","timestamp":1777315591460,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2016\/23\/D\/NZ1\/01611"],"award-info":[{"award-number":["2016\/23\/D\/NZ1\/01611"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institute of Human Genetics Polish Academy of Sciences","award":["Minigrant no. 2021\/06"],"award-info":[{"award-number":["Minigrant no. 2021\/06"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Appl Genetics"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Burkitt lymphoma (BL) is a highly aggressive lymphoma that mainly affects children and young adults. Chemotherapy is effective in young BL patients but the outcome in adults is less satisfactory. Therefore, there is a need to enhance the cytotoxic effect of drugs used in BL treatment. Glutathione (GSH) is an important antioxidant involved in processes such as regulation of oxidative stress and drug detoxification. Elevated GSH levels have been observed in many cancers and were associated with chemoresistance. We previously identified GCLC, encoding an enzyme involved in GSH biosynthesis, as an essential gene in BL. We now confirm that knockout of GCLC decreases viability of BL cells and that the GCLC protein is overexpressed in BL tissues. Moreover, we demonstrate that buthionine sulfoximine (BSO), a known inhibitor of GCLC, decreases growth of BL cells but does not affect control B cells. Furthermore, we show for the first time that BSO enhances the cytotoxicity of compounds commonly used in BL treatment, doxorubicin, and cyclophosphamide. Given the fact that BSO itself was not toxic to control cells and well-tolerated in clinical trials, combination of chemotherapy with BSO may allow reduction of the doses of cytotoxic drugs required to obtain effective responses in BL patients.<\/jats:p>","DOI":"10.1007\/s13353-023-00797-1","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T12:01:38Z","timestamp":1698926498000},"page":"95-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inhibition of the glutamate-cysteine ligase catalytic subunit with buthionine sulfoximine enhances the cytotoxic effect of doxorubicin and cyclophosphamide in Burkitt lymphoma cells"],"prefix":"10.1007","volume":"65","author":[{"given":"Marta","family":"Kazimierska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Le\u015bniewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjan","family":"Diepstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta El\u017cbieta","family":"Kasprzyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Podralska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Rassek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"Kluiver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Rozwadowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-2114","authenticated-orcid":false,"given":"Agnieszka","family":"Dzikiewicz-Krawczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"797_CR1","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/pbc.25594","volume":"62","author":"CP Anderson","year":"2015","unstructured":"Anderson CP, Matthay KK, Perentesis JP, Negila JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP (2015) Pilot study of intravenous melphalan combined with continuous infusion L-S, R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatr Blood Cancer 62:1739\u20131746","journal-title":"Pediatr Blood Cancer"},{"key":"797_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0009-2797(97)00164-6","volume":"112","author":"HH Bailey","year":"1998","unstructured":"Bailey HH (1998) L-S,R-buthionine sulfoxymine: historical development and clinical issues. Chem Biol Interact 112:239\u2013254","journal-title":"Chem Biol Interact"},{"key":"797_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1200\/JCO.1994.12.1.194","volume":"12","author":"HH Bailey","year":"1994","unstructured":"Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR (1994) Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 12:194\u2013205. https:\/\/doi.org\/10.1200\/JCO.1994.12.1.194","journal-title":"J Clin Oncol"},{"key":"797_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/jcp.56.3.188","volume":"56","author":"C Bellan","year":"2003","unstructured":"Bellan C, Lazzi S, De Falco G, Nyongo A, Giordano A, Leoncini L (2003) Burkitt\u2019s lymphoma: new insights into molecular pathogenesis. J Clin Pathol 56:188\u2013192. https:\/\/doi.org\/10.1136\/jcp.56.3.188","journal-title":"J Clin Pathol"},{"key":"797_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0009-2797(97)00166-X","volume":"111\u2013112","author":"X Chen","year":"1998","unstructured":"Chen X, Carystinos GD, Batist G (1998) Potential for selective modulation of glutathione in cancer chemotherapy. Chem Biol Interact 111\u2013112:263\u2013275. https:\/\/doi.org\/10.1016\/S0009-2797(97)00166-X","journal-title":"Chem Biol Interact"},{"key":"797_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1101\/gad.189365.112","volume":"26","author":"CV Dang","year":"2012","unstructured":"Dang CV (2012) Links between metabolism and cancer. Genes Dev 26:877\u2013890. https:\/\/doi.org\/10.1101\/gad.189365.112","journal-title":"Genes Dev"},{"key":"797_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu11081926","volume":"11","author":"E Desideri","year":"2019","unstructured":"Desideri E, Ciccarone F, Ciriolo MR (2019) Targeting glutathione metabolism: partner in crime in anticancer therapy. Nutrients 11:1\u201312. https:\/\/doi.org\/10.3390\/nu11081926","journal-title":"Nutrients"},{"key":"797_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437.Optimized","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34:184\u2013191. https:\/\/doi.org\/10.1038\/nbt.3437.Optimized","journal-title":"Nat Biotechnol"},{"key":"797_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/BF00173503","volume":"4","author":"RT Dorr","year":"1986","unstructured":"Dorr RT, Liddil JD, Soble MJ (1986) Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine cells. Investig New Drugs 4:305\u2013313","journal-title":"Investig New Drugs"},{"key":"797_CR10","first-page":"511","volume":"49","author":"L Dusre","year":"1989","unstructured":"Dusre L, Mimnaugti EG, Myers CE, Sinha BK (1989) Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res 49:511\u2013515","journal-title":"Cancer Res"},{"key":"797_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/mutage\/ger084","volume":"27","author":"A Dzikiewicz-Krawczyk","year":"2012","unstructured":"Dzikiewicz-Krawczyk A, Mosor M, Januszkiewicz D, Nowak J (2012) Impact of heterozygous c.657-661del, p.I171V and p.R215W mutations in NBN on nibrin functions. Mutagenesis 27:337\u2013343. https:\/\/doi.org\/10.1093\/mutage\/ger084","journal-title":"Mutagenesis"},{"key":"797_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3892\/ijo.25.2.413","volume":"25","author":"S Fujimori","year":"2004","unstructured":"Fujimori S, Abe Y, Nishi M, Hamamoto A, Inoue Y, Ohnishi Y, Nishime C, Matsumoto H, Yamazaki H, Kijima H, Ueyama Y, Inoue H, Nakamura M (2004) The subunits of glutamate cysteine ligase enhance cisplatin resistance in human non-small cell lung cancer xenografts in vivo. Int J Oncol 25:413\u2013418. https:\/\/doi.org\/10.3892\/ijo.25.2.413","journal-title":"Int J Oncol"},{"key":"797_CR13","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1016\/s0021-9258(18)35980-5","volume":"254","author":"OW Griffith","year":"1979","unstructured":"Griffith OW, Meister A (1979) Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254:7558\u20137560. https:\/\/doi.org\/10.1016\/s0021-9258(18)35980-5","journal-title":"J Biol Chem"},{"key":"797_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/9780470123195.ch7","volume":"73","author":"OW Griffith","year":"1999","unstructured":"Griffith OW, Mulcahy RT (1999) The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase. Adv Enzymol Relat Areas Mol Biol. 73:209\u201367. https:\/\/doi.org\/10.1002\/9780470123195.ch7","journal-title":"Adv Enzymol Relat Areas Mol Biol."},{"key":"797_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1124\/mol.106.024778","volume":"71","author":"D Hamilton","year":"2007","unstructured":"Hamilton D, Jian HW, Batist G (2007) Structure-based identification of novel human \u03b3-glutamylcysteine synthetase inhibitors. Mol Pharmacol 71:1140\u20131147. https:\/\/doi.org\/10.1124\/mol.106.024778","journal-title":"Mol Pharmacol"},{"key":"797_CR16","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.cmet.2019.01.020.Deubiquitinases","volume":"29","author":"IS Harris","year":"2019","unstructured":"Harris IS, Endress JE, Coloff JL, Selfors LM, Mcbrayer SK, Rosenbluth JM, Takahashi N, Dhakal S, Koduri V, Oser MG, Schauer NJ, Doherty LM, Hong AL, Kang YP, Younger ST, Doench JG, Hahn WC, Buhrlage SJ, Denicola GM et al (2019) Deubiquitinases maintain protein homeostasis and survival of cancer cells upon glutathione depletion HHS Public Access that depletion of GSH renders cancer cells dependent on DUB activity to maintain protein homeostasis and cell viability and reveal a pot. Cell Metab 29:1166\u20131181. https:\/\/doi.org\/10.1016\/j.cmet.2019.01.020.Deubiquitinases","journal-title":"Cell Metab"},{"key":"797_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2014.11.019","volume":"27","author":"IS Harris","year":"2015","unstructured":"Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, Yung KY, Brenner D, Knobbe-Thomsen CB, Cox MA, Elia A, Berger T, Cescon DW, Adeoye A, Br\u00fcstle A, Molyneux SD, Mason JM, Li WY, Yamamoto K et al (2015) Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27:211\u2013222. https:\/\/doi.org\/10.1016\/j.ccell.2014.11.019","journal-title":"Cancer Cell"},{"key":"797_CR18","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1271\/bbb.66.1500","volume":"66","author":"J Hiratake","year":"2002","unstructured":"Hiratake J, Irie T, Tokutake N, Oda J (2002) Recognition of a cysteine substrate by E. coli\u03b3-glutamylcysteine synthetase probed by sulfoximine-based transition-state analogue inhibitors. Biosci Biotechnol Biochem 66:1500\u20131514. https:\/\/doi.org\/10.1271\/bbb.66.1500","journal-title":"Biosci Biotechnol Biochem"},{"key":"797_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/jjco\/hyy013","volume":"48","author":"N Hiyama","year":"2018","unstructured":"Hiyama N, Ando T, Maemura K, Sakatani T, Amano Y, Watanabe K, Kage H, Yatomi Y, Nagase T, Nakajima J, Takai D (2018) Glutamate-cysteine ligase catalytic subunit is associated with cisplatin resistance in lung adenocarcinoma. Jpn J Clin Oncol 48:303\u2013307. https:\/\/doi.org\/10.1093\/jjco\/hyy013","journal-title":"Jpn J Clin Oncol"},{"key":"797_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1254\/jjp.48.283","volume":"48","author":"M Ishikawa","year":"1988","unstructured":"Ishikawa M, Takayanagi G, Sasaki K (1988) Effect of buthionine sulfoximine, an inhibitor of glutathione biosynthesis, on the selenium-induced lethality in mice. Japan J Pharmacol 48:283\u2013286","journal-title":"Japan J Pharmacol"},{"key":"797_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1053\/hupa.2002.126191","volume":"33","author":"K Jarvinen","year":"2002","unstructured":"Jarvinen K, Soini Y, Kahlos K, Kinnula VL (2002) Overexpression of \u03b3-glutamylcysteine synthetase in human malignant mesothelioma. Hum Pathol 33:748\u2013755. https:\/\/doi.org\/10.1053\/hupa.2002.126191","journal-title":"Hum Pathol"},{"key":"797_CR22","unstructured":"Johnson P, Abramson J (2022) Current treatment of Burkitt lymphoma and high-grade C-cell lymphomas. Oncology 499\u2013505"},{"key":"797_CR23","doi-asserted-by":"publisher","unstructured":"Kalisz K, Alessandrino F, Beck R, Smith D, Kikano E, Ramaiya NH, Tirumani SH (2019) An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Insights Imaging. https:\/\/doi.org\/10.1186\/s13244-019-0733-7","DOI":"10.1186\/s13244-019-0733-7"},{"key":"797_CR24","doi-asserted-by":"publisher","unstructured":"Kazimierska M, Podralska M, \u017burawek M, Wo\u017aniak T, Kasprzyk ME, Sura W, \u0141osiewski W, Zi\u00f3\u0142kowska-Suchanek I, Kluiver J, van den Berg A, Rozwadowska N, Dzikiewicz-Krawczyk A (2023) CRISPR\/Cas9 screen for genome-wide interrogation of essential MYC-bound E-boxes in cancer cells. Mol Oncol. https:\/\/doi.org\/10.1002\/1878-0261.13493","DOI":"10.1002\/1878-0261.13493"},{"key":"797_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom10101429","volume":"10","author":"L Kennedy","year":"2020","unstructured":"Kennedy L, Sandhu JK, Harper ME, Cuperlovic-culf M (2020) Role of glutathione in cancer: from mechanisms to therapies. Biomolecules 10:1\u201327. https:\/\/doi.org\/10.3390\/biom10101429","journal-title":"Biomolecules"},{"key":"797_CR26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.freeradbiomed.2007.10.031","volume":"44","author":"B Marengo","year":"2008","unstructured":"Marengo B, De Ciucis C, Verzola D, Pistoia V, Raffaghello L, Patriarca S, Balbis E, Traverso N, Cottalasso D, Pronzato MA, Marinari UM, Domenicotti C (2008) Mechanisms of BSO (L-buthionine-S,R-sulfoximine)-induced cytotoxic effects in neuroblastoma. Free Radic Biol Med 44:474\u2013482. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2007.10.031","journal-title":"Free Radic Biol Med"},{"key":"797_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12061464","volume":"12","author":"F Niu","year":"2020","unstructured":"Niu F, Kazimierska M, Nolte IM, Terpstra MM, de Jong D, Koerts J, van der Sluis T, Rutgers B, O\u2019connell RM, Kok K, van den Berg A, Dzikiewicz-Krawczyk A, Kluiver J (2020) The mir-26b-5p\/kpna2 axis is an important regulator of burkitt lymphoma cell growth. Cancers 12:1\u201320. https:\/\/doi.org\/10.3390\/cancers12061464","journal-title":"Cancers"},{"key":"797_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1200\/JCO.1996.14.1.249","volume":"14","author":"PJ O\u2019Dwyer","year":"1996","unstructured":"O\u2019Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF (1996) Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 14:249\u2013256. https:\/\/doi.org\/10.1200\/JCO.1996.14.1.249","journal-title":"J Clin Oncol"},{"key":"797_CR29","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/blood.2019001880","volume":"134","author":"RI Panea","year":"2019","unstructured":"Panea RI, Love CL, Shingleton JR, Reddy A, Bailey JA, Moormann AM, Otieno JA, Ong\u2019echa JM, Oduor CI, Schroeder KMS, Masalu N, Chao NJ, Agajanian M, Major MB, Fedoriw Y, Richards KL, Rymkiewicz G, Miles RR, Alobeid B et al (2019) The whole-genome landscape of Burkitt lymphoma subtypes. Blood 134:1598\u20131607. https:\/\/doi.org\/10.1182\/blood.2019001880","journal-title":"Blood"},{"key":"797_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047.Improved","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F (2014) Improved vectors and genome-wide libraries for CRISPR screening HHS Public Access Supplementary Material. Nat Methods 11:783\u2013784. https:\/\/doi.org\/10.1038\/nmeth.3047.Improved","journal-title":"Nat Methods"},{"key":"797_CR31","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1038\/bcj.2014.45","volume":"4","author":"A Tagde","year":"2014","unstructured":"Tagde A, Singh H, Kang MH, Reynolds CP (2014) The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Blood Cancer J 4:e229\u2013e213. https:\/\/doi.org\/10.1038\/bcj.2014.45","journal-title":"Blood Cancer J"},{"key":"797_CR32","doi-asserted-by":"publisher","unstructured":"Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, Marinari UM, Domenicotti C (2013) Role of glutathione in cancer progression and chemoresistance. Oxidative Med Cell Longev 2013. https:\/\/doi.org\/10.1155\/2013\/972913","DOI":"10.1155\/2013\/972913"},{"key":"797_CR33","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/pbc.25994","volume":"63","author":"J Villablanca","year":"2016","unstructured":"Villablanca J, Volchenboum S, Cho H, Kang M, Cohn S, Anderson C, Marachelian A, Groshen S, Tsao-Wei D, Matthay K, Maris J, Hasenauer C, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds C (2016) A phase I New approaches to neuroblastoma therapy study of buthionine sulfoximine and melphalan with autologous stem cells for recurrent\/refractory high-risk neuroblastoma. Pediatr Blood Cancer 63:1349\u20131356","journal-title":"Pediatr Blood Cancer"},{"key":"797_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1126\/science.aac7041","volume":"350","author":"T Wang","year":"2015","unstructured":"Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, Lander ES, D.M.S. (2015) Identification and characterization of essential genes in the human genome. Science 350:1069\u20131101. https:\/\/doi.org\/10.1126\/science.aac7041 Identification","journal-title":"Science"},{"key":"797_CR35","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1158\/1078-0432.CCR-10-0883","volume":"16","author":"S Yang","year":"2010","unstructured":"Yang S, Evens AM, Prachand S, Singh ATK, Bhalla S, David K, Gordon LI (2010) Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata. Clin Cancer Res 16:4755\u20134768. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0883","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Applied Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-023-00797-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13353-023-00797-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-023-00797-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T08:41:51Z","timestamp":1705308111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13353-023-00797-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s13353-023-00797-1","relation":{},"ISSN":["1234-1983","2190-3883"],"issn-type":[{"value":"1234-1983","type":"print"},{"value":"2190-3883","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}